CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has entered into a worldwide license agreement around its proprietary lentiviral vector platform with ...
Stocks are often cheap for a reason, so when investors come across a company whose shares are trading for under $3.50 apiece and with a market capitalization of $350 million, that naturally raises ...
bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stockholders tender into the current agreement by May 2, 2025 SOMERVILLE, ...
In this photo illustration, a Bluebird bio logo is seen on a smartphone. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) Last month, I wrote about the company bluebird ...
Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement. Under the ...
Add Yahoo as a preferred source to see more of our stories on Google. Former Bluebird Bio CEO Nick Leschly, speaking at the opening of a Houston cell and gene therapy facility in 2018Daniel ...
CAMBRIDGE, MA: Senior research associate Lauryn Christiansen works on lentiviral gene delivery into stem cells. The work is for the treatment of ALD, Thalassemia and Sickle Cell Anemia. Bluebird bio, ...
Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher Friday after Morgan Stanley upgraded Bluebird Bio from Underweight to Equal-Weight and raised the price target to $7. Morgan Stanley analyst ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Bluebird bio will lay off about 25% of its workforce, or 95 employees, the gene therapy maker said on Tuesday, in a ...
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital Carlyle Group and SK Capital Partners increased their upfront offer to take over gene therapy maker bluebird bio , the ...
Bluebird Bio, a company that steered three gene therapies to FDA approval but struggled to commercialize them, has found the cash it needs to put those therapies on stronger financial footing by ...
Once a rising star in the biotech industry, Bluebird Bio (NASDAQ: BLUE) has had a difficult past few years. The company's shares are down by 94% since late 2018, a horrible performance by any metric.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results